Therapeutic applications for C-peptide

Details Therapeutic applications for C-peptide Therapeutic applications for C-peptide

2011-06-21

2011-06-21

Kolker, Daniel E (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S009100

Reexamination Certificate

active

07964558

ABSTRACT:
The present invention relates to administration of C-peptide in a once daily dose for use in the treatment of diabetes and diabetic complications.

REFERENCES:
patent: 2002/0077317 (2002-06-01), Das
patent: 2003/0180332 (2003-09-01), Rimpler et al.
patent: 0 132 769 (1985-02-01), None
patent: 460334 (1989-10-01), None
patent: WO 98/13384 (1998-04-01), None
patent: WO/98/13384 (1998-04-01), None
patent: WO 02/22211 (2002-03-01), None
patent: WO 02/38129 (2002-05-01), None
Johansson et al., Biochemical and Biophysical Research Communications, 295(5):1035-1040, Aug. 2, 2002.
Johansson et al., Diabetologia, 39:687-695, 1996.
Johansson et al., Diabetologia, 35:121-128 (1992).
Fernqvist-Forbes et al., Diabetologia, 36 (Suppl 1): A1-222, 1993, Abstract 483 on p. A126.
Linde B., Absorption of C-peptide after subcutaneous injection in type 1 diabetic patients, In: “C-Peptide and type 1 diabetes mellitus”, An International Symposium, Karolinska Institute, Stockholm Sweden, Sep. 23-24, 1994.
Henriksson, M. et al. (2000) “Unordered structure of proinsulin c-peptide in aqueous solution and in the presence of lipid vesicles”Cell. Mol. Life Sci. 57:337-342.
Ido, Y. et al. (1997) “Prevention of vascular and neural dysfunction of diabetic rats by c-peptide”Science277:563-566.
Johansson, J. et al. (2002) “Molecular effects of proinsulin c-peptide”Biochem. Biophys. Res. Com. 295:1035-1040.
Kamiya, H. et al. (2004) “C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes”Ann. Neurol. 56:827-835.
Kitamura, T. et al. (2001) “Proinsulin c-peptide rapidly stimulates mitogen-activated protein kinases in swiss 3t3 fibroblasts: requirement of protein kinase c. phosphoinositide 3-kinase and pertussis toxin-sensitive g-protein”Biochem. J. 355:123-129.
Pramanik, A. et al. (2001) “C-peptide binding to human cell membranes: importance of Glu27”Biochem. Biophys. Res. Com. 284:94-98.
Rigler, R. et al. (1999) “Specific binding of proinsulin c-peptide to human cell membranes”PNAS USA96:13318-13323.
Shafqat, J. et al. (2006) “Proinsulin c-peptide elicits disaggregation of insulin resulting in enhanced physiological insulin effects”Cell. Mol. Life Sci. 63:1805-1811.
Sima, A.A.F. et al. (2001) “C-peptide prevents and improves chronic type 1 diabetic polyneuropathy in the bb/wor rat”Diabetologia44:889-897.
Wahren, J. et al. (2000) “Role of c-peptide in human physiology”Am. J. Physiol. Endocrinol. Metab. 278:E-759-E768.
Wahren, J. et al. (2003) “Does c-peptide have a role in the pathophysiology of type 1 diabetes?” Chapter 29 inInternational Textbook of Diabetes, 3rdEd. Wiley pub., London.
Zhang, W. et al. (2006) “C-peptide improves neuropathy in type 1 diabetic bb/wor-rats”Diabetes Met. Res. Revs. Epub ahead of print, 9 pages.
Johansson, B-L et al; C-Peptide and Diabetic Autonomic Neuropathy; Diabetologia (Journal of the European Association for the Study of Diabetes) vol. 39; Num 6; Jun. 1996; pp. 687-695.
Sjoberg, et al., Diabetologia, 34, 423-428, 1991.
Johansson, et al., 1992, Diabetologia, 35, 1151-1158.
Johannsson, et al, 1993, J. Clin. Endocrinol & Meta, 77, 976-981.
Wahren, et al., 1994, Diabetelogia, 37, S2, S99-107.
Wahren, et al., 1996, J. Intern. Med., 240(3), 115-24.
Wu, et al., 1996, Acta Physiol. Scand, 157(2), 253-8.
Johansson, et al., 1996, Diabetologia, 39, 687-695.
Oskarsson, et al., 1997, Diabet Med., 14, 655-659.
Forst, et al., 1998, J. Clin. Invest., 101(10), 2036-41.
Forst,et al., 1998, Exp. Clin. Endocrinal. Diabetes., 106(4), 270-6.
Wahren, et al., 1998, Horm. Metab. Res., 30(1), A2-5.
Li, et al., 1999, Diabetologia, 42(8), 958-64.
Johansson, et al., 1999, Acta Physiol. Scand, 165, 39-44.
Forst, et al., 2000, Clin. Sci., 98(3), 283-90.
Johansson, et al., 2000, Diabetic Med. 17 (3) 181-189.
Sima, et al., Int J. Exp. Diabetic Res., 2(2), 145-51.
Wahren et al., 2001, Curr. Diab. Rep., 1(3), 261-6.
Zhang, et al., 2001, Int. J. Exp. Diabetic Res.
Fernqvist-Forbes, et al., 2001, Acta Physiol. Scand., 172(3), 159-65.
Huang, et al., 2002, Naunyn Schmiedebergs Arch Pharmacol., 365(1), 67-73.
Hansen, et al., 2002, Diabetes.51 3077-3082.
Forst, et al., 2002, Diabetes Care 25(6) 1096-7.
Cotter, et al., 2003, Diabetes, 52(7); 1812-7.
Johannsson, et al., 2003, Am, J. Physiol, Endocrinol., Met 285(4), E864-70.
Wahren, et al., 2003, Diabetes Med. Res. Revs., 19(5), 345-7.
Ekberg, et al., 2003, Diabetes, 52, 536-541.

Affiliated with

Also associated with

Rating

Therapeutic applications for C-peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic applications for C-peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic applications for C-peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2618698